Dr Lal Pathlabs Ltd News

Dr Lal PathLabs Q2 net profit rises 27.5% to ₹194 cr on volume growth

Dr Lal PathLabs reported a 19.6 per cent rise in Q2FY27 revenue to ₹874 crore as sample volumes grew 13.6 per cent and patient coverage increased 9 per cent

Mankind Pharma, Dr Lal: Shrikant Chouhan bullish on 2 healthcare stocks

Stocks to buy today: Shrikant Chouhan of Kotak Neo has shared a bullish view on two healthcare stocks: Mankind Pharma and Dr Lal Pathlabs.

IDBI Bank, Lal PathLabs, Welspun Living: Top stock ideas by Choice Broking

Stocks to buy today: IDBI Bank has moved above both its 50-day EMA, which indicates that the near-term trend is turning positive, says Sachin Gupta of Choice Broking.

Dr Lal PathLabs expands advanced diagnostics portfolio with genomics buy

The ₹168 crore acquisition of a 70 per cent stake in SN Genelab is expected to strengthen Dr Lal's genomics expertise and broaden its advanced diagnostics portfolio

Stocks to watch: HDFC Bank, Hyundai Motor, BSE, IDFC First Bank, SpiceJet

Stocks to watch: HDFC Bank, Hyundai Motor India, BSE, IDFC First Bank, SpiceJet, Kolte-Patil Developers, Escorts Kubota, HDFC Life, Oil India, among others, will be in focus today.

DCB Bank, Dr Lal Path among Kotak Securities' top tech ideas; here's why

Geographically, DCB has a diversified pan-India presence with a stronger footprint across western and southern India, while continuing to expand selectively into underpenetrated markets.

Dr Lal Path jumps 8% to 52-week high on Q1 beat; up to 25% upside on cards

Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of ₹1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.

Dr Lal PathLabs jumps 5% after Q1 PAT surges 21%; ₹5 dividend declared

Dr Lal PathLabs' consolidated net profit grew by 21.4 per cent Y-o-Y to ₹170 crore in Q1 of FY27.

Dividend stocks: LIC, Asian Paints, 28 others to remain in focus next week

Dividend stocks: CARE Ratings, Supreme Industries, Sona BLW Precision Forgings, and Allied Blenders and Distillers are among the companies that will go ex-dividend next week

Dr Lal PathLabs soars 11%, hits 52-week high on huge volumes; here's why

Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.

Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%

Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.